<DOC>
	<DOC>NCT01211834</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of tocilizumab vs placebo, in combination with stable, ongoing therapy, with regard to reduction in signs and symptoms in patients with moderate to severe active RA and inadequate response to current DMARD treatment</brief_summary>
	<brief_title>Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>adult patients, &gt;= 18 years of age Active RA of &gt; 6monts duration Received permitted DMARDs each at a stable dose for at least 8 weeks Rheumatic autoimmune disease other than RA Significant systemic involvement secondary to RA ALT or AST &gt; ULNâ…¹1.5 Platelet count &lt; 100,000/mm3 Hemoglobin &lt; 8.5 g/dL White blood cells &lt; 3,000/mm3 Absolute neutrophil count &lt; 2,000/mm3 Absolute lymphocyte count &lt; 500/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>